" Apotex " The Canadian Pharmaceutical Corporation

Apotex Pharmaceutical Corporation


The large Canadian pharmaceutical corporation under the name of (Apotex) which has founded in 1974 by B. Sherman, the company is large producer of drugs in Canada, with sales exceeding CAD$1 billion per year. By 2016, Apotex employed a lot of people through the Canada's largest drug manufacturers, with over 300 products selling in over 115 countries. Revenues were about CAD$1.19 billion annually.


Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure. Apotex is a member of the Canadian Generic Pharmaceutical Association (CGPA), the Generic Pharmaceutical Association (GPhA), an associate member of the Canadian Animal Health Institute (CAHI), the Canadian Association for Pharmacy Distribution Management (CAPDM), as well as the Greater Toronto Area's Partners in Project Green.


From their humble origins of only two employees, we’ve grown to employ more than 10,000 people worldwide in manufacturing, R&D and commercial operations. Through vertical integration, the Apotex Group of Companies is comprised of Apotex Generics, Apotex Active Pharmaceutical Ingredients, Apobiologix and ApoPharma (innovative products). They export for more than 115 countries and territories, and operate in more than 45 countries, including a significant presence in the US, Mexico and India where they continue to invest.


Their footprint includes an expanding network of Affiliates and Distributors, as well as joint ventures and strategic alliances. Globally, they produce approximately 25 billion doses per year, which, in turn are used to fill approximately 90 million prescriptions in Canada alone, or one in five prescriptions. Their Contribution to Sustainable Healthcare in the past five years alone, they have helped to bring more than 20 prescription drugs to market before patent expiry, and in doing so, saved public and private payers more than $4 billion. In total, they have saved Canadians almost $27 billion by bringing products to market early.


Additionally, the past 10 years, they have invested more than $1 billion in research and development, with an additional $2 billion planned for the next years.